The invention relates to a trans-epicutaneous pharmaceutical compositioncontainingRotigotine for effective treatment of Restless Leg Syndrome (RLS), especiallyin theform of a transdermal therapeutic system (TDS) based on acrylate or siliconehaving asurface of 2.5 - 20 cm2 and containing 1.125 9.0 mg/cm2 Rotigotine as anactivecomponent against Restless Leg Syndrome, which, according to the InternationalRestless Leg Syndrome Study Group (IRLSSG) Rating Scale, results in animprovementin the conditions of human Restless Leg Syndrome patients in comparison with aplacebo treatment of 2 units or more, after administration over a period oftime of atleast 8 days.
